Replies to post #263711 on Avid Bioservices Inc (CDMO)

[biopharm]

But that is not the basis on which you should have found this article interesting IMO. What is MUCH MORE pointing in the direction of Bavituximab is the ROLE of caspase 3. It is actually part of the apoptosis cycle (natural cell death) and phosphatidylserine is the ABSOLUTE #1 orchestra leader of that cycle. It binds at least 7 receptors that we know on cells during that cycle. Caspase-3 (a cysteine peptidase) is found in the apoptic cells, those cells where PS is exposed.
Caspase, when activated by apoptic signalling, actually destroys cell without discrimination and therefore must be regulated. Actually the best soldier for an hostile virus to activate.

So if I believe there could be a chance that the drug the Doctor at John Hopkins talked about could be Bavituximab then it would be based on that because IMO it is the most 'filtering' element leaving very few, if any, other drug candidates.

And remember it is a drug that is not approved yet, so we can exclude the PD-1/PD-L1 and CTLA-4 drugs because they all have been approved in some larger or smaller cancer condition.

I would think the ICDS would have some new info with Raymond Birge... Rolf Brekken upcoming about all this, especially since their home page has been showcasing that PS is exposed on the cell surface and nice to know that Peregrine Pharmaceuticals has 100% control of those PS Targeting rights

http://www.celldeath-apoptosis.org/